| Literature DB >> 35405965 |
Young-Min Ham1, Seon-A Yoon1, Hyejin Hyeon1, Ho-Bong Hyun1, Sung-Chun Kim1, Boram Go1, Yong-Hwan Jung1, Weon-Jong Yoon1.
Abstract
Green mandarins are widely consumed unripe as mandarin oranges (Citrus unshiu Marcov.), which exhibit anti-inflammatory and anti-wrinkle effects by inhibiting the production of inflammatory cytokines and matrix metalloproteinase. A randomized, double-blind, placebo-controlled clinical study was performed to verify the skin improvement efficacy and safety of green mandarin extract (PTE). For the standardization of PTE, narirutin was set as a marker compound, and PTE with a constant narirutin content was prepared for the study. After randomizing subjects with periorbital wrinkles, they were orally administered PTE (300 mg/day) or a placebo for 12 weeks. Periorbital wrinkles were measured using PRIMOSCR SF. Skin elasticity, moisture content, transepidermal water loss, and gloss were also measured. In the study results, the depth, volume, and skin roughness of the periorbital wrinkles were significantly improved compared to the control group (p = 0.011, 0.009, and 0.004, respectively). The survey confirmed that the skin condition improved after PTE consumption for 12 weeks. No adverse reactions associated with PTE were observed during the study period. Thus, the results demonstrate that PTE effectively improves UV-induced skin wrinkles. Therefore, it is considered that PTE has sufficient value as a functional food ingredient that can prevent skin aging.Entities:
Keywords: Citrus unshiu Marcov.; Putgyul extract; functional food; narirutin; skin aging
Mesh:
Substances:
Year: 2022 PMID: 35405965 PMCID: PMC9002563 DOI: 10.3390/nu14071352
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Study flow chart. Flow diagram of the progress though the phase of a parallel randomized trial of two groups (enrollment, allocation, follow-up, completion and data analysis).
Figure 2Active compound contained in PTE (A) and a HPLC chromatogram (B) of narirutin from PTE.
Baseline characteristics A.
| Placebo ( | PTE ( | ||
|---|---|---|---|
| Gender (N, male/female) | 0/40 | 0/40 | - |
| Age (years) | 46.2 ± 3.9 | 47.1 ± 4.4 | 0.314 |
| BMI (kg/m) | 23.5 ± 2.8 | 22.7 ± 3.0 | 0.244 |
| SBP (mmHg) | 113.1 ± 13.1 | 111.1 ± 13.4 | 0.519 |
| DBP (mmHg) | 78.5 ± 5 | 75.2 ± 11.2 | 0.144 |
A Mean ± standard error of the mean. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure. B p-value by independent t-test.
Figure 3Change from baseline values of skin wrinkles on the crow’s feet during PTE treatment. p-value by independent t-test; * p < 0.05, ** p < 0.005.
Change in wrinkle parameters measured by PRIMOSCR SF (Canfield, NJ, USA).
| Parameter | Visit | PTE ( | Placebo ( | # | ## | ||||
|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD | Median | Min, Max | Mean ± SD | Median | Min, Max | ||||
| Avg.wrinkle depth | Week 0 | 58.63 ± 14.040 | 55.0 | 39.0, 91.0 | 55.73 ± 9.915 | 57.5 | 36.0, 77.0 | 0.290 | 0.649 |
| Week 12 | 57.68 ± 14.543 | 53.5 | 35.0, 94.0 | 56.89 ± 10.752 | 58.0 | 33.0, 78.0 | 0.790 | 0.594 | |
| Change | −0.95 ± 4.188 | −1.0 | −10.0, 7.0 | 1.51 ± 4.107 | 1.0 | −6.0, 10.0 | 0.011 * | 0.024 * | |
| Wrinkle volume | Week 0 | 7.48 ± 2.293 | 7.1 | 3.8, 13.1 | 7.16 ± 1.804 | 7.3 | 3.5, 10.2 | 0.483 | 0.766 |
| Week 12 | 6.87 ± 2.185 | 6.3 | 3.6, 12.5 | 6.78 ± 1.820 | 7.0 | 2.8, 10.0 | 0.838 | 0.768 | |
| Change | −0.61 ± 0.583 | −0.6 | −2.2, 0.5 | −0.28 ± 0.488 | −0.4 | −1.2, 0.9 | 0.009 ** | 0.017 * | |
| Roughness area | Week 0 | 29.04 ± 6.516 | 27.4 | 18.7, 45.8 | 27.84 ± 4.834 | 28.2 | 19.1, 39.1 | 0.354 | 0.785 |
| Week 12 | 28.07 ± 6.686 | 26.3 | 17.4, 45.9 | 28.14 ± 5.133 | 27.3 | 16.7, 38.4 | 0.956 | 0.506 | |
| Change | −0.97 ± 1.948 | −1.0 | −4.4, 3.7 | 0.43 ± 2.133 | −0.1 | −3.1, 5.0 | 0.004 ** | 0.009 ** | |
| Mean depth biggest wrinkle | Week 0 | 92.80 ± 38.260 | 89.0 | 33.0, 202.0 | 89.93 ± 38.254 | 82.5 | 38.0, 217.0 | 0.738 | 0.578 |
| Week 12 | 90.53 ± 37.694 | 90.0 | 35.0, 206.0 | 89.43 ± 37.946 | 81.0 | 39.0, 223.0 | 0.900 | 0.867 | |
| Change | −2.28 ± 9.498 | −1.5 | −24.0, 21.0 | −0.76 ± 10.145 | 1.0 | −33.0, 18.0 | 0.500 | 0.259 | |
| Max depth biggest wrinkle | Week 0 | 352.35 ± 222.127 | 327.0 | 83.0, 1115.0 | 308.05 ± 155.214 | 255.5 | 101.0, 694.0 | 0.390 | 0.490 |
| Week 12 | 333.73 ± 201.506 | 295.5 | 87.0, 963.0 | 308.54 ± 170.860 | 257.0 | 103.0, 870.0 | 0.558 | 0.655 | |
| Change | −18.63 ± 51.793 | −12.5 | −229.0, 86.0 | −2.81 ± 62.583 | −3.0 | −164.0, 215.0 | 0.230 | 0.299 | |
| Wrinkle area | Week 0 | 126.62 ± 18.148 | 135.6 | 85.6, 145.0 | 127.24 ± 17.042 | 135.4 | 93.6, 145.1 | 0.875 | 0.927 |
| Week 12 | 118.30 ± 16.146 | 126.5 | 82.5, 139.3 | 117.53 ± 16.524 | 125.2 | 86.8, 136.7 | 0.837 | 0.895 | |
| Change | −8.31 ± 4.059 | −7.0 | −18.0, −2.4 | −8.69 ± 3.335 | −7.8 | −19.0, −3.5 | 0.661 | 0.423 | |
| Length of wrinkle | Week 0 | 192.28 ± 35.695 | 201.5 | 118.0, 253.0 | 201.68 ± 26.586 | 203.5 | 143.0, 264.0 | 0.186 | 0.336 |
| Week 12 | 176.58 ± 30.836 | 184.5 | 113.0, 229.0 | 183.30 ± 25.500 | 188.0 | 133.0, 234.0 | 0.303 | 0.453 | |
| Change | −15.70 ± 10.920 | −16.0 | −42.0, 11.0 | −16.73 ± 10.090 | −17.0 | −39.0, 10.0 | 0.669 | 0.811 | |
p < 0.05 *, p < 0.01 **, #: Independent t-test, ##: Wilcoxon’s rank sum test.
Changes from baseline value of biomarkers in skin.
| Variable | Group | Week 0 | Week 4 | Week 8 | Week 12 | Significance | |
|---|---|---|---|---|---|---|---|
| Factor |
| ||||||
| Skin | PTE | 41.44 ± 5.86 | 42.14 ± 6.20 | 43.18 ± 6.40 | 44.34 ± 6.67 | Group ## | 0.772 |
| Placebo | 41.42 ± 4.56 | 41.42 ± 4.91 | 41.88 ± 5.04 | 42.91 ± 5.35 | Time † | 0.001 *** | |
| 0.793 | 0.627 | 0.338 | 0.306 | Group × Time ‡ | 0.057 | ||
| Skin | PTE | 74.41 ± 5.22 | 74.81 ± 5.15 | 75.40 ± 5.24 | 74.81 ± 5.31 | Group ## | 0.300 |
| Placebo | 75.69 ± 4.33 | 76.12 ± 4.08 | 76.17 ± 4.33 | 76.29 ± 4.57 | Time † | 0.003 *** | |
| 0.240 | 0.221 | 0.487 | 0.196 | Group × Time ‡ | 0.170 | ||
| Skin glowing | PTE | 3.37 ± 0.97 | 3.76 ± 0.98 | 3.86 ± 1.01 | 3.90 ± 1.02 | Group ## | 0.094 |
| Placebo | 3.41 ± 0.92 | 3.44 ± 0.80 | 3.46 ± 0.86 | 3.55 ± 0.87 | Time † | 0.001 *** | |
| 0.154 | 0.129 | 0.066 | 0.111 | Group × Time ‡ | 0.486 | ||
| Transepidermal water loss | PTE | 15.09 ± 4.14 | 14.78 ± 3.77 | 15.10 ± 4.83 | 14.64 ± 3.61 | Group ## | 0.0.211 |
| Placebo | 16.25 ± 4.48 | 16.19 ± 3.64 | 15.44 ± 3.10 | 15.34 ± 2.69 | Time † | 0.114 | |
| 0.233 | 0.101 | 0.710 | 0.346 | Group × Time ‡ | 0.227 | ||
p < 0.001 ***. #: t-Test of between groups. ##: between the placebo group and treatment group with repeated measure ANOVA. †: within groups according to the duration of the trial with repeated measure ANOVA. ‡: p value for interaction between time and group by ANOVA for repeated measurements (time × group) between the placebo and the treatment.
Survey results on product efficacy.
| Variable | Group | Week 4 | Week 8 | Week 12 | Significance | |
|---|---|---|---|---|---|---|
| Factor |
| |||||
| Increase skin moisture | PTE | 3.33 ± 0.57 | 3.63 ± 0.62 | 3.63 ± 0.58 | Group ## | 0.599 |
| Placebo | 3.22 ± 0.63 | 3.65 ± 0.48 | 3.54 ± 0.65 | Time † | 0.001 *** | |
| 0.430 | 0.855 | 0.550 | Group × Time ‡ | 0.620 | ||
| Increase skin gloss | PTE | 3.20 ± 0.56 | 3.63 ± 0.58 | 3.60 ± 0.67 | Group ## | 0.182 |
| Placebo | 3.14 ± 0.48 | 3.41 ± 0.49 | 3.46 ± 0.69 | Time † | 0.001 *** | |
| 0.590 | 0.082 | 0.369 | Group × Time ‡ | 0.563 | ||
| Increase skin elacsticity | PTE | 3.25 ± 0.58 | 3.55 ± 0.55 | 3.65 ± 0.70 | Group ## | 0.066 |
| Placebo | 3.22 ± 0.58 | 3.27 ± 0.45 | 3.38 ± 0.59 | Time † | 0.001 *** | |
| 0.801 | 0.018 * | 0.071 | Group × Time ‡ | 0.151 | ||
| Improvement crow’s feet | PTE | 3.05 ± 0.50 | 3.25 ± 0.49 | 3.65 ± 0.58 | Group ## | 0.337 |
| Placebo | 3.11 ± 0.39 | 3.22 ± 0.53 | 3.35 ± 0.67 | Time† | 0.001 *** | |
| 0.5770. | 0.744 | 0.040 * | Group × Time ‡ | 0.025 * | ||
| Improvement total skin condition | PTE | 3.40 ± 0.54 | 3.68 ± 0.52 | 3.90 ± 0.59 | Group ## | 0.138 |
| Placebo | 3.32 ± 0.62 | 3.62 ± 0.54 | 3.57 ± 0.64 | Time † | 0.001 *** | |
| 0.573 | 0.663 | 0.021 * | Group × Time ‡ | 0.106 | ||
p < 0.05 *, p < 0.001 ***. #: t-Test of between groups, ##: between the placebo group and treatment group with repeated-measure ANOVA. †: within groups according to the duration of the trial with repeated-measure ANOVA. ‡: p value for interaction between time and group by ANOVA for repeated measurements (time × group) between the placebo and the treatment.